Says therapeutic portfolio ‘demonstrating very strong momentum’ into 2025. Says making “significant progress” in R&D efforts. Invest with ...
Says well-positioned with ex-Humira platform for 2025. Sees clear runway for growth “for at least eight years.” Expects Skyrizi and Rinvoq to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback